P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis

Abstract

Background and Aims: Increases of lipid levels associated with inflammatory bowel disease (IBD) treatment have been previously reported. However, it is unknown if this effect is similar for all IBD drug classes. Method(s): We performed a systematic literature search of randomized controlled trials and observational cohort studies of IBD treatment with corticosteroids, anti TNFalpha agents and tofacitinib that assessed total cholesterol (TC) before and after short-term ( =12 week) treatment. Data of 11 studies (1,663 IBD patients) were pooled using a random effect model with as primary outcome TC levels. Lipid changes were reported as mean difference on the log2-scale (MD log2) with 95% CI. The effect of patient and disease characteristics on TC changes were analyzed 6 studies with individual patient data of 1,211 patients. Result(s): A significant increase in TC was observed after treatment with corticosteroids, anti TNFalpha agents and tofacitinib (short-term +0.370, +0.197 and +0.190; long-term: +0.452, +0.068 and +0.162, respectively). (Figure 1) After correcting for age, sex, BMI and CRP, TC levels increased most after start of corticosteroids followed by tofacitinib treatment (short-term: +0.288 and +0.079, respectively), but significantly decreased in anti TNFalpha agents (short-term: -0.062). (Figure 2) [Formula presented] [Formula presented] Conclusion(s): TC levels increase was strongest for corticosteroids followed by tofacitinib but not observed for anti TNFalpha agents. Whether TC change associated with IBD treatment has effect on CVD risk requires further study. Copyright © 2021